- Project Scoping & Target Design
We collaborate with you to define objectives, select the optimal ncAA chemistry, and design the target gene construct with specified incorporation sites.
Genetic code expansion (GCE) is an innovative technology that allows for the site-specific incorporation of non-canonical amino acids (ncAAs) into proteins, thereby installing precisely defined chemical functionalities, such as bioorthogonal reactive groups, spectroscopic probes, or mimics of post-translational modifications (PTMs). As a leader in integrating preclinical expertise with cutting-edge biotechnology, our company has pioneered a proprietary GCEngine platform for developing orthogonal aaRS/tRNA pairs. This platform empowers the precise engineering of proteins with novel properties, enabling advanced applications in pharmaceutical R&D, synthetic biology, and diagnostic development.
Protein engineering is a powerful approach used to define structure-function relationships by creating and characterizing mutant forms of proteins. Moving beyond the limitations of nature's standard amino acid repertoire, ncAA incorporated protein engineering leverages GCE to create proteins with precisely installed, user-defined chemical handles or functional groups. By introducing ncAAs bearing diverse moieties, including bioorthogonal reaction partners, PTM mimics, fluorophores, or crosslinkers, researchers can endow target proteins with tailored biochemical and biophysical characteristics. This technology provides superior control over protein function, stability, interactions, and localization, opening new avenues in drug discovery, enzyme engineering, therapeutic protein optimization, and biomaterial design.
Fig. 1 ncAAs employed in protein engineering. (Zhou, K. Z. Q., et al., 2024)
Harnessing a proprietary GCEngine platform, we offer a seamless, end-to-end workflow for ncAA incorporated protein engineering. This comprehensive service spans from initial bioinformatic design and high-throughput screening for optimal orthogonal aaRS/tRNA pairs identification, through rigorous in vitro validation of ncAA incorporation efficiency and fidelity, to final in vivo expression and functional characterization, accelerating the path from concept to functional, engineered proteins.
Focused on the most challenging frontiers of drug discovery, the GCEngine platform enables the development of next-generation biologics and vaccines across several critical therapeutic modalities.
ncAA Incorporated Protein Therapeutic Development
Enabling the next generation of biotherapeutics through site-specific PEGylation for improved pharmacokinetics, creation of stable, long-acting analogs, and engineering of irreversible (covalent) binding motifs for enhanced target engagement.
ncAA Incorporated Cytokine Engineering
Modifying cytokines and growth factors to fine-tune receptor binding specificity, modulate signaling half-life, and improve thermal and conformational stability, potentially reducing immunogenicity and enhancing therapeutic index.
ncAA Incorporated Epitope Optimization for Vaccine
Strategically introducing ncAAs into antigenic epitopes to stabilize specific conformational states, enhance binding to neutralizing antibodies, or create hydrolytically stable antigen mimics for more potent and durable immune responses.
ncAA Incorporated Protein Vaccine Development
Constructing well-defined, self-adjuvanting vaccines by site-specifically linking immunogenic carriers or antigen units to TLR agonists or other immune potentiators via bioorthogonal handles introduced via ncAAs.
Driven by a commitment to technical excellence and scientific integrity, our team delivers the advanced GCE solutions. By choosing our GCEngine platform, you gain access to a deep reservoir of proprietary aaRS/tRNA libraries and a streamlined workflow designed to accelerate your R&D timelines from discovery to preclinical validation. To explore how our ncAA incorporated protein engineering services can advance your specific program, please contact our scientific business development team for a detailed consultation.
All our services are exclusively intended for preclinical research purposes. They are not intended for diagnostic, therapeutic, or patient management applications.
A specialized platform advancing genetic code expansion through orthogonal tRNA/aaRS technologies, enabling precise ncAA incorporation for biotherapeutic development, synthetic biology, and diagnostics.